Charles DeBattista

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult)

Clinical Focus

Psychiatry
Clinical Psychopharmacology
Resistant Depression
Neuromodulation

Academic Appointments

Professor - University Medical Line, Psychiatry and Behavioral Sciences
Member, Wu Tsai Neurosciences Institute

Honors & Awards

Fellow, American College of Psychiatrists (2022)
Nancy C.A. Roeske, M.D. Award for Excellence in Medical Student Education, American Psychiatric Association (2018)
Teacher of the Year, Dept. Of Psychiatry (1998, 2000, 2001)

Professional Education

Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2007)
Fellowship: Stanford University Psychiatry and Behavioral Sciences (1993) CA
Residency: Stanford University Adult Psychiatry Residency (1993) CA
Internship: Stanford University Adult Psychiatry Residency (1990) CA
Medical Education: University of California at San Francisco School of Medicine (1989) CA
DMH, UCSF/UC Berkeley, Mental Health (1986)
MD, UCSF, Medicine (1989)

Contact

Academic debattista@stanford.edu Tel: (650) 723-8324

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Psychiatry Department 401 Quarry Rd Rm 2303 MC 5723 Stanford CA 94305 Tel: (650) 498-9111 Fax: (650) 724-9900

Additional Clinical Info

Stanford Health Care

Current Research and Scholarly Interests

Treatment resistant depression.

Novel biological interventions in the treatment of mental illness.

Anti-glucocorticoid drugs in the treatment of mood disorders.

Augmentation strategies in the treatment of depression.

Clinical Trials

Tianeptine for Treatment Resistant Depression Recruiting
More
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of Medicine (SUSM). In addition, MRI studies for the MSSM patients will be carried out at the New York State Psychaitric Institute (NYSPI). The following procedures will be approved by the local Institutional Review Boards (IRBs) at each site, where the site PIs (Alla Landa, PhD, NYSPI, James Murrough, MD at MSSM, and Alan Schatzberg, MD at SUSM) will be responsible for overseeing conduct of the study at their respective site. Dr. Jonathan Javitch is the scientific leader of this program and holds the IND for tianeptine use in this study. Investigators will recruit 75 participants with current unipolar MDD, non-delusional, between 21-60, who have failed at least 2 two adequate treatment trials with a standard antidepressant. Patients will receive an 8-week treatment trial of tianeptine. MSSM patients will also undergo structural and task-based magnetic resonance imaging (MRI) that will be performed under Dr. Landa's direction at NYSPI in order to maintain the internal validity of the data set. MSSM subjects will be transported to NYSPI to complete neuroimaging procedures as described below. Participants will be screened for MRI clearance during their screening visit and again at NYSPI on the day of the scan. Subjects will be asked MRI screening questions to ensure that are scanning eligible. Participants will also have additional tubes of blood drawn for human whole-genomic testing. This microarray will be used to identify regions of the human genome that contribute to disease susceptibility and phenotypes. The Illumina human whole-genome array will be used to provide a comprehensive view of the genome, detects single nucleotide polymorphisms and other variations across the genome.
Lead Sponsor
Stanford Investigators
- Jason Tucciarone, MD, PhD
- Charles DeBattista
View full details
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD Recruiting
More
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
Lead Sponsor
Stanford Investigators
- Charles DeBattista
View full details
Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression Not Recruiting
More
This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

Stanford is currently not accepting patients for this trial. For more information, please contact Jessica Hawkins, 6507238323.

Lead Sponsor
- Stanford University
Stanford Investigators
- Charles DeBattista
View full details
Functional MRI Before and After Treatment for Depression Not Recruiting
More
The purpose of this study is to help us understand how depression changes brain activity and how this relates to mood, anxiety, and cognitive functions like memory. We also hope to develop a brain imaging test that will predict either before or within two weeks of starting a medicine whether the treatment will work.

Stanford is currently not accepting patients for this trial. For more information, please contact Maureen H Chang, B.S., 650-725-4620.

Lead Sponsor
- Stanford University
Stanford Investigators
- Charles DeBattista
View full details
Radiosurgical Neuromodulation for Refractory Depression Not Recruiting
More
This study is designed to evaluate the safety and effectiveness of an investigational procedure for treating people with treatment resistant bipolar depression (TRD). Precise dose delivery of radiation to the predetermined targets in the brain will be accomplished with known Cyberknife stereotactic radiosurgery methods. This technology is considered to be noninvasive (does not physically invade your body). We will be studying if the Cyberknife influences the sensitivity of certain nerves of your brain. Although many clinical treatments for psychiatric conditions have been done using stereotactic radiosurgery, the present study is experimental, because we are seeking to use more moderate doses of radiation that are intended not to destroy any brain cells, but to normalize or modulate their function.

Stanford is currently not accepting patients for this trial. For more information, please contact Jessica Hawkins, 6507238323.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Treatment Trial for Psychogenic Nonepileptic Seizures Recruiting
More
The investigators propose that patients who receive targeted pharmacotherapy (sertraline) or focused psychotherapy (cognitive behavioral therapy-informed psychotherapy (CBT-ip) for NES) or combined treatment (CBT-ip + sertraline) will report fewer nonepileptic seizures (NES) compared to patients who receive community care / treatment as usual (TAU). The purpose of this study is to provide pilot testing and data to inform the future multicenter randomized controlled trial based on the hypothesis.
Lead Sponsor
Stanford Investigators
- Charles DeBattista
View full details
Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder Not Recruiting
More
The purpose of the study is to explore the efficacy of 6 weeks treatment of an investigational medication, RO4995819, versus placebo as adjunctive therapy in patients with major depression.

Stanford is currently not accepting patients for this trial. For more information, please contact Maureen Chang, B.S., 650-725-4620.

Lead Sponsor
- Stanford University
Stanford Investigators
- Hugh Brent Solvason PhD MD
- Charles DeBattista
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Psychiatry
  PSYC 299 (Aut, Win, Spr, Sum)
- Graduate Research
  PSYC 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PSYC 370 (Aut, Win, Spr, Sum)
- Teaching in Psychiatry
  PSYC 290 (Aut, Win, Spr, Sum)
- Undergraduate Research, Independent Study, or Directed Reading
  PSYC 199 (Aut, Win, Spr, Sum)

Stanford Advisees

Med Scholar Project Advisor
Maha Zubaidi

Graduate and Fellowship Programs

Psychiatry and Behavioral Science (Fellowship Program)

All Publications

Profiles With Related Publications

close
Elias Aboujaoude, MD, MA

Clinical Professor, Psychiatry and Behavioral Sciences

62 Total Publications
close
Bruce Arnow, Ph.D.

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult)
Clinical Focus
Depression, Psychotherapy, Clinical Psychology
Research Interests
Current research interests include treatment outcome for major depression, particularly treatment refractory and chronic forms of major depression, as well as mediators and moderators of outcome; the epidemiology of chronic pain and depression; relationships between child maltreatment and adult sequelae, including psychiatric, medical and health care utilization.

129 Total Publications
close
Jacob S. Ballon

Associate Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)
Clinical Focus
Psychiatry, psychosis, schizophrenia, early psychosis

45 Total Publications
close
Christine Blasey

Clinical Professor, Psychiatry and Behavioral Sciences

74 Total Publications
close
Katherine Eisen

Clinical Associate Professor, Psychiatry and Behavioral Sciences
Clinical Focus
Cognitive Behavioral Therapy for Psychosis, Early Intervention for Psychosis, Clinical Psychology

11 Total Publications
close
Ian Gotlib

David Starr Jordan Professor
Research Interests
Current interests include social, cognitive, and biological factors in affective disorders; neural and cognitive processing of emotional stimuli and reward by depressed persons; behavioral activation and anhedonia in depression; social, emotional, and biological risk factors for depression in children.

584 Total Publications
close
Jennifer Keller

Clinical Professor, Psychiatry and Behavioral Sciences
Clinical Focus
Clinical Psychology
Research Interests
interpersonal violence and abuse prevention; empowerment of women; cognitive and affective information processing in depression; clinical, biological, and neuropsychological aspects of depression; South Asian mental health

44 Total Publications
close
Terence Ketter

Professor of Psychiatry and Behavioral Sciences (Psychopharmacology), Emeritus
Research Interests
The use of brain imaging methods for understanding the neurobiology of mood disorders and to target treatments for patients with bipolar disorders. Research in the use of novel medications and combinations of medications in the treatment of bipolar disorders. Research on the development and course of bipolar disorder in late adolescence and young adulthood, particularly in college students, and links between creativity, temperament, and mood disorders.

467 Total Publications
close
Lorrin Koran

Professor (Clinical) of Psychiatry and Behavioral Sciences, Emeritus
Research Interests
obsessive-compulsive disorder, depressive disorders, psychopharmacology, cost-effectiveness studies, trichotillomania, compulsive buying, pathological gambling,kleptomania.

159 Total Publications
close
Helena Chmura Kraemer

Professor of Biostatistics in Psychiatry, Emerita
Research Interests
I am interested in the methodology pertinent to dealing with research problems where biological and behavioral interests meet. These interests have been applied not only in psychiatric research, but in those areas of Cardiology, Pediatrics and other fields of medicine in which behavioral research is becoming ever more salient.

481 Total Publications
close
Philip W. Lavori

Professor of Biomedical Data Science, Emeritus
Research Interests
Biostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.

342 Total Publications
close
Anna Lembke, MD

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult)
Clinical Focus
Addiction Medicine, Pain and Addiction, Prescription Drug Misuse and Addiction, Behavioral Addictions (Gaming, Gambling, Sex, Shopping)

73 Total Publications